Reference 2021-51

REF: 2021-51          

Subject: Information on biologic drugs for Dermatology     

 

Request:

Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

  • Adalimumab – Humira
  • Adalimumab Biosimilar
  • Apremilast
  • Brodalumab
  • Certolizumab
  • Dimethyl fumarate
  • Etanercept – Enbrel
  • Etanercept Biosimilar
  • Guselkumab
  • Infliximab – Remicade
  • Infliximab Biosimilar
  • Ixekizumab
  • Risankizumab
  • Secukinumab
  • Tildrakizumab
  • Ustekinumab

 

Q2. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

  • Adalimumab – Humira
  • Adalimumab Biosimilar
  • Golimumab
  • Infliximab – Remicade
  • Infliximab Biosimilar
  • Tofacitinib
  • Ustekinumab
  • Vedolizumab

 

Q3. If possible, could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for Ulcerative Colitis ONLY with the following biologic drugs:

  • Adalimumab – Humira
  • Adalimumab Biosimilar
  • Golimumab
  • Infliximab – Remicade
  • Infliximab Biosimilar
  • Tofacitinib
  • Ustekinumab
  • Vedolizumab

 

 

Response:

Please find response attached.

 

2021-51 – FOI Request – Information on biologic drugs for Dermatology [156 KB PDF]